Myriad Genetics

myriad.com

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

BIONTECH AND MEDIGENE ANNOUNCE GLOBAL COLLABORATION TO ADVANCE T CELL RECEPTOR IMMUNOTHERAPIES AGAINST CANCER

BioNTech SE | February 22, 2022

news image

BioNTech SE and Medigene AG a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. Medigene&rsqu...

Read More

INDUSTRIAL IMPACT

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

news image

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More

AI

DEARGEN ANNOUNCES NEW MODEL FOR OPTIMIZING DRUG CANDIDATE MOLECULES WITH NEARLY DOUBLED PERFORMANCE COMPARED TO EXISTING MODELS

Deargen | April 12, 2021

news image

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...

Read More

MEDTECH

BIOCYTOGEN LISTS ON THE MAIN BOARD OF HKEX, AIMING TO BECOME THE HEADSTREAM OF NEW DRUGS

Biocytogen | September 02, 2022

news image

Biocytogen Pharmaceuticals Co., Ltd. nnounced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony. In total, 21.76 million shares were offered globally with a price of HK$ 25.22 per share. The net proceeds from the Global Offering will be approximately HK$ 471.1 million. Since its establishment in 2009, Biocyt...

Read More
news image

INDUSTRIAL IMPACT

BIONTECH AND MEDIGENE ANNOUNCE GLOBAL COLLABORATION TO ADVANCE T CELL RECEPTOR IMMUNOTHERAPIES AGAINST CANCER

BioNTech SE | February 22, 2022

BioNTech SE and Medigene AG a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. Medigene&rsqu...

Read More
news image

INDUSTRIAL IMPACT

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More
news image

AI

DEARGEN ANNOUNCES NEW MODEL FOR OPTIMIZING DRUG CANDIDATE MOLECULES WITH NEARLY DOUBLED PERFORMANCE COMPARED TO EXISTING MODELS

Deargen | April 12, 2021

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...

Read More
news image

MEDTECH

BIOCYTOGEN LISTS ON THE MAIN BOARD OF HKEX, AIMING TO BECOME THE HEADSTREAM OF NEW DRUGS

Biocytogen | September 02, 2022

Biocytogen Pharmaceuticals Co., Ltd. nnounced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony. In total, 21.76 million shares were offered globally with a price of HK$ 25.22 per share. The net proceeds from the Global Offering will be approximately HK$ 471.1 million. Since its establishment in 2009, Biocyt...

Read More